JNJ

Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises
Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises
Endpoints
AstraZeneca
Calquence
clinical trials
chronic lymphocytic leukemia
AbbVie
JNJ
Imbruvica
Flag link:
Where Will Johnson & Johnson Be in 10 Years?
Where Will Johnson & Johnson Be in 10 Years?
Motley Fool
JNJ
Flag link:
Marketing J&J eyes prostate cancer boost as FDA accepts Erleada for real-time review
Marketing J&J eyes prostate cancer boost as FDA accepts Erleada for real-time review
Fierce Pharma
JNJ
Erleada
FDA
prostate cancer
metastatic castration-resistant prostate cancer
Flag link:
J&J's quest to detect lung cancer before it emerges
J&J's quest to detect lung cancer before it emerges
Fierce Biotech
JNJ
smoking
lung cancer
MRNA
biomarkers
Flag link:
Arrowhead starts triple-combo hepatitis B test, triggering J&J payday
Arrowhead starts triple-combo hepatitis B test, triggering J&J payday
Fierce Biotech
Arrowhead Pharmaceuticals
JNJ
clinical trials
hepatitis B
ARO-HBV
Flag link:
What does the past generation of failure in Alzheimer’s R&D look like in one slide?
What does the past generation of failure in Alzheimer’s R&D look like in one slide?
Endpoints
R&D
Alzheimer's disease
amyloid beta
Eli Lilly
Pfizer
JNJ
Flag link:
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Fierce Pharma
AbbVie
Celgene
JNJ
Merck
Pfizer
Vertex Pharmaceuticals
investors
executive pay
Flag link:
Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up
Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up
Fierce Pharma
Bayer
JNJ
Xarelto
bloodthinners
Bristol-Myers Squibb
Pfizer
Eliquis
Flag link:
Most people pay less than $5 per month for the drug. But some pay $11,002
Most people pay less than $5 per month for the drug. But some pay $11,002
Stat
JNJ
Janssen
Stelara
drug pricing
Flag link:
Johnson & Johnson Rises After Topping First-Quarter Earnings Forecasts
Johnson & Johnson Rises After Topping First-Quarter Earnings Forecasts
TheStreet.com
JNJ
earnings
Flag link:
J&J, Merck and Pfizer spent tax savings on investor payouts, not R&D: Oxfam
J&J, Merck and Pfizer spent tax savings on investor payouts, not R&D: Oxfam
Fierce Pharma
taxes
tax cuts
investors
R&D
Merck
JNJ
Pfizer
Flag link:
Forward Guidance Will Make or Break JNJ Earnings
Forward Guidance Will Make or Break JNJ Earnings
NASDAQ
JNJ
earnings
Flag link:
Outracing 2 giant rivals, J&J touts promising PhIII Invokana data as a game-changer for kidney disease risks
Outracing 2 giant rivals, J&J touts promising PhIII Invokana data as a game-changer for kidney disease risks
Endpoints
JNJ
Invokana
diabetes
kidney disease
Flag link:
Pfizer, AstraZeneca and J&J Take Issue With FDA’s List of Companies Withholding Drug Samples
Pfizer, AstraZeneca and J&J Take Issue With FDA’s List of Companies Withholding Drug Samples
RAPS.org
generics
Pfizer
AstraZeneca
JNJ
Flag link:
J&J's Balversa gets accelerated approval for bladder cancer
J&J's Balversa gets accelerated approval for bladder cancer
BioCentury
JNJ
Janssen
Balversa
bladder cancer
FDA
Flag link:
Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med
Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med
Endpoints
JNJ
HIV
Symtuza
social media
twitter
Flag link:
The top 15 pharma companies by 2018 revenue
The top 15 pharma companies by 2018 revenue
Fierce Pharma
JNJ
Roche
Pfizer
Novartis
Merck
GSK
Sanofi
AbbVie
Bayer
Eli Lilly
Amgen
Bristol-Myers Squibb
Gilead Sciences
Teva Pharmaceutical
AstraZeneca
Flag link:
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
Pharmaceutical Business Review
ViiV Healthcare
Dolutegravir
rilpivirine
JNJ
Janssen
HIV
Flag link:
Eyeing a fast pitch for quick OK in race with bluebird, J&J/Legend team enjoys a regulatory embrace for their rival BCMA CAR-T
Eyeing a fast pitch for quick OK in race with bluebird, J&J/Legend team enjoys a regulatory embrace for their rival BCMA CAR-T
Endpoints
JNJ
Legend Biotech
JNJ-68284528
CAR-T
BCMA
Flag link:
Holobiome and J&J collaborate for second time for microbiome therapeutics
Holobiome and J&J collaborate for second time for microbiome therapeutics
Pharma Times
JNJ Innovation
JNJ
Holobiome Corporation
microbiome
Flag link:

Pages